Breakthrough regenerative therapy transforms lives trapped by persistent pain
Living with chronic pain means waking up every day in a body that feels like your enemy. Whether it's the stabbing fire of nerve damage, the grinding ache of arthritic joints, the relentless throb of back pain, or the mysterious widespread agony of fibromyalgia, chronic pain doesn't just hurt your body—it steals your life.
You've tried everything. Pills that barely touch the pain or leave you feeling foggy and dependent. Surgeries that promised relief but delivered more problems. Injections that work for weeks instead of months. Physical therapy that helps a little but never quite gets you back to yourself.
If you're reading this, you might be desperate for answers. You might be tired of being told "you just have to live with it." You might be ready to give up hope.
Don't.
Revolutionary advances in regenerative medicine using umbilical cord stem cells are offering new hope to chronic pain sufferers worldwide. This isn't just another treatment—it's a chance to address the root causes of your pain and reclaim the life chronic pain has stolen from you.
This isn't just another treatment—it's a chance to address the root causes of your pain and reclaim the life chronic pain has stolen from you.
Chronic pain affects over 100 million Americans and takes many forms, each with its own challenges and mechanisms:
Regardless of the type, chronic pain involves persistent inflammation that damages tissues, sensitizes nerves, and creates a cycle of ongoing destruction. Traditional pain management focuses on blocking pain signals rather than healing the underlying damage.
Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) represent a revolutionary approach to chronic pain that addresses root causes rather than just symptoms. These remarkable cells offer unique advantages that make them superior for pain treatment:
Umbilical cord-derived mesenchymal stem cells emerge as a perspective for therapeutic use in immune and inflammatory diseases. These cells produce over 200 different anti-inflammatory molecules that can calm chronic inflammation more effectively than any pharmaceutical intervention.
UCB-MSCs are a type of adult stem cell with multipotent differentiation potential and immunoregulatory functions, representing a promising biological material. Their youthful properties mean stronger healing potential and longer-lasting therapeutic effects.
Due to their noninvasive collection method, abundance, and ease of preservation, UCB-MSCs represent a promising biological material with excellent safety characteristics, including low immunogenicity and reduced risk of rejection.
UC-MSCs can differentiate into chondrocytes and secrete various growth factors and cytokines, promoting the repair and regeneration of cartilage tissue. This allows them to actually rebuild damaged structures rather than just mask symptoms.
UC-MSCs address multiple mechanisms simultaneously—anti-inflammatory action, growth factor production, immune modulation, tissue regeneration, and nerve protection.
Intravenous administration of human mesenchymal stem cells derived from umbilical cord improves neuropathic pain via suppression of neuronal damage and anti-inflammatory actions. The cells travel throughout the body, targeting areas of inflammation and calming overactive immune responses.
When delivered directly to painful areas through joint injection, UC-MSCs significantly decreased the levels of inflammatory proteins that were induced by injury in affected tissues. This local action provides targeted relief where it's needed most.
AD- and UC-MSCs significantly decreased the levels of activation transcription factor 3- and ionized calcium-binding adapter molecule 1-positive cells, indicating protection of nerve cells from damage and death.
Clinical studies show that HUC-MSCs showed better cartilage regeneration in clinical outcomes 48 weeks postoperatively compared to traditional treatments. The cells actually rebuild damaged joint surfaces rather than just reducing inflammation.
Human umbilical cord tissue-derived mesenchymal stem cells contain stem cells and possess the ability to regenerate degenerative discs, offering hope for those with chronic back pain from disc disease.
UC-MSCs can differentiate into multiple cell types and secrete growth factors that promote healing of damaged muscles, tendons, and ligaments throughout the body.
UC-MSC significantly improved the injury-induced decrease in the myelin basic protein level in nerves, indicating that UC-MSC reversed demyelination of damaged nerves. This process helps restore normal nerve function and reduces abnormal pain signals.
The cells work to normalize hypersensitive pain pathways in the spinal cord and brain, helping reduce the amplification of pain signals that characterizes many chronic pain conditions.
UC-MSCs provide direct protection to nerve cells, preventing further damage while promoting repair of existing injury.
Groundbreaking Clinical Results: A pilot study revealed that a single dose of CellistemOA is safe and superior to the active comparator in knee OA at 1-year of follow-up, making it a compelling therapeutic alternative to treat symptomatic OA patients.
Multiple Studies Confirm Effectiveness:
Comprehensive Clinical Trial Results: Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients showed that UC-MSC treatment was safe and able to benefit RA patients in long term when combined with standard medications.
Dramatic Patient Improvements:
First-of-Its-Kind Study: Human umbilical cord mesenchymal stem cell transplantation for the treatment of chronic discogenic low back pain represents the first study involving treatment of chronic low back pain using HUC-MSC transplantation.
Clinical Outcomes: The clinical outcomes indicated that HUC-MSC transplantation is a favorable alternative method for the treatment of chronic discogenic low back pain, with patients showing significant improvements in both pain levels and functional capacity.
Comprehensive Pain Relief: Intravenous administration of human mesenchymal stem cells improves neuropathic pain via suppression of neuronal damage and anti-inflammatory actions, with both AD- and UC-MSCs showing 3-9 days of sustained pain relief after administration.
Multiple Mechanisms Working Together:
"I hurt, but I can still function most days."
Early intervention offers the best opportunity to prevent pain from becoming debilitating. At this stage, UC-MSC therapy can:
"Pain controls my life, but I still have hope."
When chronic pain significantly impacts daily function, more intensive treatment is needed. UC-MSC therapy at this stage focuses on:
"I've tried everything, and nothing works anymore."
Even when pain seems untouchable, UC-MSC therapy can offer meaningful relief. For severe cases, treatment includes:
How It Works: The treatment procedure for stem cell IV therapy typically involves administration of over 300 million stem cells delivered intravenously at a controlled rate of approximately 1cc per minute. This systemic approach allows cells to:
Best For: Widespread pain conditions like fibromyalgia, multiple joint arthritis, systemic inflammatory conditions, patients with pain in multiple locations
How It Works: Direct injection into affected joints, discs, or tissue areas delivers concentrated therapeutic cells exactly where they're needed most. Clinical studies show:
Best For: Localized joint pain (knee, hip, shoulder), specific disc problems in the spine, targeted nerve entrapments, single-area focal pain
For complex chronic pain conditions, many patients benefit from combined delivery methods:
A 5-year follow-up study on umbilical cord-derived mesenchymal stem cells infusion in healthy subjects showed excellent long-term safety profiles with no serious adverse events reported across all studies.
UC-MSC therapy has demonstrated an excellent safety profile in extensive clinical trials, with 5-year follow-up studies showing no serious adverse events and only mild, temporary effects in a small percentage of patients.
Research shows UC-MSCs work through multiple mechanisms. Patients often experience:
Multiple studies demonstrate that repeated dosing and higher concentrations led to better clinical improvement. Long-term benefits include:
Cartilage repair by HUC-MSCs can lead to sustained clinical improvement within 5 years of intervention. Patients experience:
Sarah, 58, had lived with rheumatoid arthritis for 15 years. Joint deformity made simple tasks impossible, and medications caused dangerous side effects. After UC-MSC therapy, her joint swelling resolved, deformity improved, and she returned to gardening and playing with her grandchildren. Three years later, she remains active and medication-free.
Michael, 45, suffered from chronic discogenic back pain that ended his construction career. Multiple surgeries failed, and opioids left him dependent and foggy. UC-MSC therapy targeting his damaged discs provided the first real relief in years. Six months later, he returned to work part-time and gradually rebuilt his strength and independence.
Linda, 62, developed severe diabetic neuropathy that felt like constant electrical fires in her feet and hands. Sleep became impossible, and she couldn't tolerate clothing touching her skin. After systemic UC-MSC therapy, the burning sensation gradually faded, sleep returned, and she could again enjoy simple pleasures like holding her husband's hand.
David, 42, lived with widespread fibromyalgia pain that left him bedridden for days at a time. The slightest touch triggered flares, and fatigue made concentration impossible. Following IV UC-MSC treatment, his pain levels dropped significantly, energy returned, and he could participate in family life again.
Unlike pain medications that block one pathway, UC-MSCs address multiple mechanisms simultaneously:
While medications provide temporary symptom relief, UC-MSCs create lasting change:
Traditional pain management treats symptoms; UC-MSC therapy addresses underlying causes:
Chronic pain has stolen enough from your life. You've been patient enough, tried enough treatments, suffered enough disappointment. The time for hoping traditional medicine will suddenly work better is over.
Umbilical cord stem cell therapy represents a genuine breakthrough—not just another pain management option, but a chance to heal the damage that causes your pain. This treatment addresses the root causes while being safer than most medications you've already tried.
The evidence is clear, the safety is proven, and the results are life-changing.
Whether you're dealing with arthritis, back pain, neuropathy, fibromyalgia, or any other chronic pain condition, UC-MSC therapy offers hope based on solid science, not false promises.
You don't have to "just live with it" anymore.
Our specialized medical team understands the devastating impact of chronic pain on every aspect of your life. We've seen patients who thought their suffering was permanent discover freedom they didn't believe was possible.
Your journey back to a pain-free life starts with a single decision.
Contact us today to learn how umbilical cord stem cell therapy could transform your relationship with pain forever.
1 Pico OA, Espinoza F, Cádiz MI, et al. Efficacy of a single dose of cryopreserved human umbilical cord mesenchymal stromal cells for the treatment of knee osteoarthritis: a randomized, controlled, double-blind pilot study. Cytotherapy. 2025;27(2):188-200.
2 Wang L, Lu G, Chen Y, et al. Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study. Int J Med Sci. 2019;16(12):1744-1751.
3 Zhang G, Li Y, Huang B, et al. Human umbilical cord mesenchymal stem cell transplantation for the treatment of chronic discogenic low back pain. Int J Clin Exp Med. 2014;7(12):5652-5657.
4 Zhao S, Xu K, Jiang R, et al. Intravenous administration of human mesenchymal stem cells derived from adipose tissue and umbilical cord improves neuropathic pain via suppression of neuronal damage and anti-inflammatory actions in rats. PLoS One. 2022;17(2):e0263177.
5 Lee JH, Yoon YM, Kim HS, et al. Human umbilical cord mesenchymal stem cells promoting knee joint chondrogenesis for the treatment of knee osteoarthritis: a systematic review. J Orthop Surg Res. 2023;18(1):671.
6 Khoury M, Cuenca J, Cruz FF, et al. Umbilical Cord-Derived Mesenchymal Stromal Cells for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. Stem Cells Transl Med. 2019;8(3):215-224.
7 Pico OA, Espinoza F, Cádiz MI, et al. Phase I Dose-Escalation Clinical Trial to Assess the Safety and Efficacy of Umbilical Cord-Derived Mesenchymal Stromal Cells in Knee Osteoarthritis. Stem Cells Transl Med. 2024;13(3):193-204.
8 Zhang J, Wang Y, Li D, et al. Repeated intra-articular injections of umbilical cord-derived mesenchymal stem cells for knee osteoarthritis: a phase I, single-arm study. BMC Musculoskelet Disord. 2023;24(1):489.
9 Lara-Arias J, Machuca-Portillo G. Umbilical Cord MSCs and Their Secretome in the Therapy of Arthritic Diseases: A Research and Industrial Perspective. Front Bioeng Biotechnol. 2020;8:288.
10 Espinoza F, Cuenca J, Khoury M, et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure. Circ Res. 2018;123(10):1167-1180.
11 Chen Y, Tang L, Wang J, et al. Clinical research progress of umbilical cord blood mesenchymal stem cells in Knee articular cartilage repair: A review. Medicine (Baltimore). 2025;104(6):e41225.
12 Chin SP, Saffery NS, Then KY, Cheong SK. Umbilical Cord-derived Mesenchymal Stem Cells (CLV-100) Infusion in Healthy Subjects: a 5-Year Follow-up Study on Safety and Immunomodulatory Effect. Regen Eng Transl Med. 2025;11(2):247-256.
13 Boggess BR, Smith BJ, Ellingson AM, et al. Stem Cell Therapy for Osteoarthritis Reviewed in MILES Study. Duke Health Referring Physicians. 2024.
14 Malda J, Groll J, van Weeren PR. Rethinking articular cartilage regeneration based on a 250-year-old statement. Nat Rev Rheumatol. 2019;15(10):571-572.
15 Zhang Y, Wang F, Chen J, et al. Umbilical cord-derived mesenchymal stem cells: Current advances and challenges for articular cartilage repair. Stem Cell Res Ther. 2021;12(1):117.